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In the past decades, there have been major advances in unraveling the pathophysiology 
and –biology of pulmonary arterial hypertension (PAH), its classification and treatment 
options. The introduction of the PAH-targeted drugs and implementation of evidence-
based treatment guidelines have strongly improved quality of life and survival in adults 
with PAH. Unfortunately, due to several unique features of pediatric PAH, including the 
frequent occurrence of genetic or congenital anomalies and the influence of growth 
and developmental issues on disease progression, outcome and pharmacokinetics 
and –dynamics, adult data cannot be simply extrapolated to children with PAH. Data 
in pediatric PAH remain scarce. The aims of this thesis were to provide more insights 
and knowledge towards optimal classification, treatment strategies and outcome by 
characterizing the subgroup of pediatric PAH associated with congenital heart disease 
(PAH-CHD) and assessing the value of the Nice congenital heart disease classification 
(Nice-CHD-classification), by describing current treatments and treatment strategies 
and their effect on outcome, by describing survival and its predictors in children with 
PAH in the current era of PAH-targeted drugs, and by evaluating the value a potential 
clinical endpoint for pediatric randomized controlled trials (RCTs). In this chapter, the 
main findings of this thesis will be discussed including directions for future research.
TowardS oPTimal ClaSSifiCaTioN iN PediaTriC Pah
Pulmonary hypertension (PH) is a symptom of a heterogeneous spectrum of diseases 
with various pathological, pathophysiological, clinical and therapeutic differences. Dur-
ing the 2nd World Symposium on PH (Evian, France, 1998) a clinical classification for PH 
consisting of five major subgroups based on pathological, pathophysiological, clinical 
and therapeutic similarities was presented for the first time. Since then, this classification 
has been modified several times according to evolving insights and was last updated 
during the 5th World Symposium on PH in Nice, France, 2013 (Nice classification).1 During 
this World Symposium, a pediatric task force was included for the first time. Ideally, a 
classification system could be used to predict pace and risk of disease progression and 
to determine the optimal treatment strategy for each individual patient.
In pediatric PAH, idiopathic PAH (IPAH) and PAH-CHD are most common.2-4 Other forms 
of PAH are less common2-4, which is confirmed by the small part (6%) of children with 
associated PAH other than CHD in the cohort presented in Chapter 7. In this cohort, we 
showed that children with PAH-CHD had better and children with associated PAH other 
than CHD had worse survival compared to children with IPAH, independent from patient 
characteristics and disease severity. Data on whether survival of children with PAH-CHD 
is indeed favorable compared to that of children with IPAH are contradictory.2,5,6 Sev-
eral studies report favorable survival of children with PAH-CHD, whereas others report 
182
Chapter 9
similar, or at least not favorable, survival of this group compared to IPAH.2,5,6 A major 
reason for this discrepancy is the fact that PAH-CHD comprises a heterogeneous group 
of patients, especially in children. The broad variety in CHD and extracardiac comorbidi-
ties plays an important role in this heterogeneity.7 Furthermore, in the past, not all CHD 
have been strictly classified as PAH-CHD. For instance, CHD regarded not sufficient to ex-
plain the development of childhood PAH has often been classified as IPAH, or IPAH-like. 
Thus, different classification and inclusion criteria in studies could have led to different 
study populations impeding definitive conclusions regarding expected disease course, 
response to therapy and outcome in different subtypes of pediatric PAH.
Since the updated clinical classification of PH in 2009, it has been proposed to further 
classify PAH-CHD into Eisenmenger syndrome, PAH associated with left-to-right shunt, 
PAH with coincidental CHD and post-operative PAH (Nice-CHD-classification).1,8 Al-
though this classification has been shown to identify differences in patient and disease 
characteristics and survival in adults9, data in pediatric PAH were lacking. We report 
in Chapter 2 that a conventional shunt-based classification and the new Nice-CHD-
classification identify groups with specific patient and disease characteristics in pedi-
atric PAH. Therefore, these classifications may be useful in children as well. However, an 
important limitation of these classifications is that there is no place for non-shunt CHD 
which forms a substantial part (10-15%) of pediatric PAH-CHD. In our cohort, non-shunt 
CHD included aortic coarctation, repaired total anomalous pulmonary venous return, 
unilateral absence of a pulmonary artery, Scimitar syndrome and transposition of the 
great arteries (TGA) repaired with arterial switch operation (ASO) in the neonatal period. 
Non-shunt CHD certainly deserves and requires a place in any optimal classification, as 
the PAH severely worsens prognosis also in these patients. Recently, a clinical classifica-
tion system specifically for pediatric PAH was proposed, the Panama classification.10 The 
Panama classification aims to comprise the complete spectrum of childhood PH and 
consists of 10 major categories and more than 100 subgroups. One category includes 
‘pediatric heart disease’, which in itself consists of more than 15 subcategories. Con-
sequently, all non-shunt CHD have a place in this classification, mostly in the ‘pediatric 
heart disease’ category. However, this many subgroups will lead to very small numbers 
in each group, especially in a rare disease as pediatric PAH, hampering the purpose 
of risk stratification and tailored treatment approaches. Therefore, a balance between 
being all-inclusive and adequate simplicity is key in an optimal classification.11 Future 
efforts should be directed towards further refinement of the Nice-CHD-classification in 
order to provide a home for the complete spectrum of CHD associated with childhood 
PAH including non-shunt CHD.
The subgroup of PAH after neonatal ASO for TGA is of particular interest as this con-
currence is a well recognized clinical entity in pediatric PH centers. However, a clinical 




cohort of 25 children with PAH after neonatal ASO for TGA. We estimate the reported 
incidence of this association to be 0.6-1.0% of children who undergo neonatal ASO for 
TGA. Hemodynamic abnormalities very early in life, either pre- or perinatally, may play 
an important role in the development of PAH in these children.12 That hemodynamics 
early in life may form an important determinant in the development and course of child-
hood PAH is also illustrated by children with so-called ‘accelerated’ PAH.3 Children with 
an unrepaired non-restrictive post-tricuspid shunt-defect, such as a ventricular septal 
defect, normally develop PAH in the first years of life with a gradual increase in pulmo-
nary vascular resistance, eventually resulting in reversal of the shunt and Eisenmenger 
syndrome.13 However, in Chapter 2 we report three children that presented with Eisen-
menger physiology already in the first half year after birth and all died. Such children 
with ‘accelerated’ PAH have been previously reported to have very poor prognosis.3 In 
these children, the pulmonary vascular bed may not adapt normally to postnatal life 
which may lead to severe persistent pulmonary hypertension of the newborn and/or 
advanced PAH early in life.
A unique feature of pediatric PAH is the fact that organs and tissues in fetal life and 
early childhood are developing and maturing. Developmental, genetic or congenital 
anomalies may hamper or alter normal organ development/maturing, which could lead 
to perinatal maladaptation and pulmonary vascular disease early in life. Furthermore, 
prenatal pathological or environmental insults may harm the growing lung which could 
lead to underdevelopment of the pulmonary vasculature or pulmonary hypoplasia.10,11,14 
As such, these factors may play a modifying role in the development and progression of 
PAH10,11,14, which indeed seems to be the case in the abovementioned subgroups of PAH-
CHD. In contrast to the Panama classification, the role of such developmental or mal-
adaptive factors in pediatric PAH, including altered pre- and perinatally hemodynamics, 
is currently insufficiently acknowledged in the Nice(-CHD-)classification.1,10 Although 
improvements in this respect have been made by the pediatric task force during the 5th 
World Symposium, the Nice classification would benefit from further improvements in 
acknowledging and providing a home for fetal/perinatal and developmental factors in 
pediatric PAH.
TowardS oPTimal TreaTmeNT STraTegieS
Pah-targeted drugs in pediatric Pah
In pediatric PAH, treatment efficacy data and the development of evidence-based treat-
ment guidelines are delayed due to a virtual absence of RCTs. Currently, only one of 
the PAH-targeted drugs is approved for children in Europe and none of these drugs is 
approved for children in the United States. We summarized the limited available data 
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on efficacy and safety of the PAH-targeted drugs in pediatric PAH in Chapter 4. Recently, 
both a consensus statement and guideline for the treatment of pediatric PAH have be-
come available, which provide classes of recommendation and levels of evidence for the 
use of PAH-targeted drugs.15,16 Although the PAH-targeted drugs received either class 
of recommendation I or IIa, level of evidence was either B or C indicating that data are 
limited or very limited. In contrast, in the latest adult guidelines the ‘older’ PAH-targeted 
drugs all have class of recommendation I with level of evidence A and the ‘newer’ ones 
have class of recommendation I with level of evidence B.17 Without downgrading the 
importance of expertise of the treating physicians in pediatric PAH, this illustrates the 
high need for RCTs in pediatric PAH.
A major problem in the development of RCTs in pediatric PAH is the lack of a vali-
dated endpoint. Such an endpoint should be clinically meaningful, i.e. it should reflect 
how a patient feels, functions or survives.18 Death may seem a robust endpoint, since 
improving prognosis is a main objective in (pediatric) PAH. However, using death as 
an endpoint requires long study durations and large study groups, which are both not 
feasible nor preferable in a rare and progressive disease as PAH.19,20 Therefore, this would 
not be ethically justified precluding death as a useful endpoint in (pediatric) PAH. In 
adults, the six-minute walk distance (6MWD) has been used as primary endpoint in most 
pivotal RCTs.21-23 In children with PAH, this is not a feasible endpoint since it cannot be 
reliably performed in infants and young children nor in children with physical and/or 
mental developmental delays. In the Sildenafil in Treatment-Naive Children, Aged 1 to 17 
Years, With Pulmonary Arterial Hypertension (STARTS-1) RCT, the percent change from 
baseline peak oxygen consumption measured during cardiopulmonary exercise testing 
(CPET) was used as primary endpoint.24 However, CPET has the same limitations as the 
6MWD regarding young age and developmental delays, but is also a more complex test 
for both the child and physician. In STARTS-1, CPET could only be performed in 115 out 
of 234 included children and was evaluable in only 106 children (45%).24 This illustrates 
that CPET cannot be regarded a feasible endpoint in pediatric PAH.
Accelerometry, a non-invasive and relatively cheap tool, has been proposed as a 
potential endpoint in pediatric PAH.20,25 In Chapter 8 we showed that accelerometry 
is feasible in children of various ages and that physical activity measured by acceler-
ometry was markedly decreased in children with PAH compared to healthy, age- and 
sex-matched controls. As accelerometer output represents physical activity and thereby 
a direct reflection of how a patient functions, it can be regarded a clinically meaning-
ful endpoint. Furthermore, accelerometer output correlated considerably with clinical 
disease severity markers and outcome.
Time to clinical worsening, which has been used as primary endpoint in more recent 
adult PAH RCTs26,27, has also been proposed as study endpoint in pediatric PAH.20,28 It is 




ponents include death and lung transplantation, whereas soft components can include 
hospitalization, the need for therapy escalation or balloon atrial septostomy, progres-
sion of symptoms and functional deterioration defined by worsening 6MWD and/
or World Health Organization functional class (WHO-FC). Recently, our group showed 
that the clinical worsening composite occurs early and frequently in the follow-up of 
children with PAH and that all components were highly predictive for death.29 In clinical 
worsening, accelerometry may be of value as addition to or alternative for the 6MWD as 
soft component. This could make clinical worsening more applicable in children of all 
ages further strengthening its use as study endpoint in pediatric PAH.
Treatment strategies in pediatric Pah
For the oral and inhaled PAH-targeted drugs, based on pharmacokinetics and pharma-
codynamics, rather strict dosing recommendations exist for their use in adults and chil-
dren. In contrast, reported doses for subcutaneous and intravenous (IV/SC) prostanoids 
are less clear and vary significantly between studies.5,30-32 Target doses as suggested in 
recent guidelines show a broad range, which may be insufficient to guide clinicians.15,16 
Furthermore, data regarding discontinuation of IV/SC prostanoids and transition to oral/
inhaled therapies are very limited in pediatric PAH.33,34 Given the unsatisfactory survival 
in pediatric PAH and in the search for optimal treatment strategies, data regarding the 
‘when, how and for how long’ of IV/SC prostanoids would be very valuable. In Chapter 5, 
we provide a current clinical practice description regarding the use of IV/SC prostanoids 
in pediatric PAH, which were used in 36% of the children included in the original cohort 
as presented in Chapter 7. We show that approximately one-third of children is tran-
sitioned to oral/inhaled therapy and that successful transition with good longer-term 
outcome is predicted by near-normalization of pulmonary hemodynamics. In contrast, 
if there is no such normalization, even when the child is in WHO-FC I-II, transition to 
oral/inhaled therapy should not be considered. Furthermore, higher doses of IV/SC 
prostanoids may have beneficial effects on outcome, which appears to be independent 
from disease severity and time of IV/SC prostanoids initiation. As these data come from 
a retrospective cohort not specifically designed to evaluate the use of IV/SC prostanoids 
therapy, further studies specifically designed for this purpose are warranted.
Previously, treatment was often not escalated until a patient deteriorated. Due to 
evolving insights, a more aggressive goal-oriented treatment strategy is now being 
adopted in both adult and pediatric PAH.35,36 This means that treatment is not only esca-
lated when a patient deteriorates but also when a patients does not improve sufficiently, 
i.e. does not reach treatment goals within a period of therapy. Treatment goals, i.e. 
predefined improvements in clinical or hemodynamic parameters, are used to monitor 
clinical status and treatment efficacy in the individual patient and to guide treatment 
decisions.11 Such parameter improvements could serve as treatment goals if they either 
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represent improved quality of life, e.g. improvement of exercise capacity, or a decrease 
in the chance of an outcome event, e.g. death or lung transplantation. In the latter 
case, the parameter has to meet the three criteria for surrogacy. First,   the parameter 
should predict outcome. Secondly, it should be influenced by the given therapy, and 
thirdly such treatment-induced changes should reflect changes in outcome.37,38 Thus, a 
parameter predicting outcome does not automatically qualify as parameter that could 
be used as treatment goal. In Chapters 6 and 7 we identified WHO-FC, plasma levels of 
(N-terminal pro) brain natriuretic peptide ([NTpro]BNP) and several hemodynamics ob-
tained during cardiac catheterization (cardiac index, mean right atrial pressure, indexed 
pulmonary vascular resistance, mean pulmonary-to-systemic artery pressure ratio and 
acute vasodilator response) as disease characteristics significantly predicting outcome. 
Although these parameters may all be influenced by therapy, there is currently only 
limited evidence regarding treatment-induced changes in both adult and pediatric PAH. 
In children, treatment-induced changes in WHO-FC and plasma levels of  NTproBNP (and 
also tricuspid annular plane systolic excursion) were recently shown to predict survival 
and improving these parameters thus qualifies as treatment goal in pediatric PAH.38 
Several echocardiographic parameters and cardiac magnetic resonance measurements 
have also been shown to predict outcome39-43 but the current lack of data hampers their 
validation as treatment goals. A major advantage of accelerometry is that it provides 
a direct and objective measurement of how a patient functions, which could directly 
reflect quality of life. Improving accelerometer output, i.e. improving physical activity, 
therefore qualifies as valid treatment goal and could help guide treatment decisions in 
pediatric PAH.
In combination therapy with two or three PAH-targeted drugs, each targeting a differ-
ent pathway, the drugs may have a synergistic effect on each other. Indeed, combination 
therapy, both upfront and add-on, has been shown to have beneficial effects on clinical 
status and outcome in adult PAH, which was recently confirmed in a systematic review 
and meta-analysis.27,44-47 In children with PAH, data regarding combination therapy are 
scarce. Nevertheless, sildenafil add-on therapy was shown to have beneficial effects 
in children who deteriorate on bosentan therapy alone.48 Furthermore, addition of 
inhaled or subcutaneous prostanoids to oral PAH-targeted therapy may be beneficial in 
a subset of children.49,50 The data presented in Chapter 7 support the beneficial effects of 
combination therapy compared to monotherapy as children who received dual or triple 
PAH-targeted therapy during their disease course had favorable outcome compared to 
children who received only monotherapy, independent from disease severity.
Importantly, the value of non-drug treatments should not be forgotten in a time in 
which especially drug therapies receive so much attention. In fact, striving to optimal 
drug treatment strategies should not lead to too late non-drug treatments, such as 




the Potts shunt, i.e. a direct anastomosis between the left pulmonary artery and aorta, 
should be further established. In patients with suprasystemic pulmonary artery pres-
sure, the Potts shunt leads to a direct pressure reduction of the right ventricle with 
systemic desaturation only in the lower parts of the body. To date, experiences seem 
favorable51,52, but larger study groups may be required to reliably assess its value. As 
donor lungs remain scarce and will not come in time to save all children with end-stage 
PAH, the Potts shunt may serve as a bridge-to-transplantation or may even lead to defer-
ring the need for lung transplantation in selected patients.52
Future studies should be directed towards providing efficacy and safety data for (com-
bination) PAH-targeted therapy and the goal-oriented treatment strategy. Also, studies 
should be directed towards gathering further support for currently identified treatment 
goals and assessing the value of other parameters that may serve as treatment goals. 
Furthermore, the value of non-drug treatments, especially the Potts shunt, should be 
further evaluated.
TowardS oPTimal ouTCome
There are quite large survival differences between different reporting centers/cohorts 
in pediatric PAH.2,5,53-56 In Chapter 7 we showed that unadjusted survival rates differed 
between the three center cohorts. Importantly, these survival differences disappeared 
when correcting for disease severity. This confirms that reported survival rates cannot 
be simply compared to each other, since differences in inclusion criteria, selection of 
patients and the role of the referral center as regional or national referral center may 
lead to survival differences. Consequently, differences in reported survival rates do not 
simply reflect differences in quality of care or treatment strategies and should thus be 
interpreted with care. A careful and complete description of the studied cohort will help 
to identify potential differences between studies enhancing interpretation of (discrep-
ancies in) reported survival rates.
Nowadays, reported 3- to 5-year transplantation-free survival rates of pediatric PAH 
range from approximately 60% to 85%2,5,6,55-57, which is in line with the survival rates re-
ported in this thesis. Although this indicates that survival of pediatric PAH has improved 
in recent years, it also shows that that 15% to 40% of children with PAH die or undergo 
lung transplantation within 3 to 5 years after diagnosis, which is obviously unsatisfac-
tory and undesirable.
Optimal outcome, including both survival and quality of life, may be achieved by opti-
mizing classification and treatment strategies in pediatric PAH. As none of the currently 
available PAH treatments can cure PAH, the development of new therapies is also of 
great interest. In pediatric PAH, gathering data for evaluating the value of classifications 
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or treatment strategies faces and will face several challenges inherent to the rareness 
and heterogeneity of pediatric PAH. One important challenge is how to obtain large 
enough study populations but there may be several solutions for this challenge. First, 
combining patient cohorts into multicenter or even multinational registries will increase 
study sizes. In recent years, such initiatives have led to valuable data in relatively large 
study groups and include the multinational Tracking Outcomes and Practice in Pedi-
atric Pulmonary Hypertension (TOPP) registry and the United States-based Registry to 
Evaluate Early and Long-Term Pulmonary Arterial Disease Management (REVEAL).4,6 Fur-
thermore, a collaboration between three major referral centers for pediatric PAH formed 
the basis for three Chapters of this thesis and resulted in one of the largest cohorts in 
pediatric PAH to date. It is important to keep in mind that in order to achieve compara-
bility between patients from different centers, using strict and uniform inclusion criteria 
is essential in such collaborations. Secondly, as the care for pediatric PAH patients is 
centralized in many countries, including France, Spain, the United Kingdom and the 
Netherlands, there are national cohorts reporting on pediatric PAH.2,3,53,56,57 Combining 
national cohorts may also lead to larger study groups. Combining (national) cohorts can 
also be used to find answers to specific questions. To illustrate this, bringing together all 
children with PAH after neonatal ASO for TGA from several (national) cohorts allowed for 
the first clinical characterization of this association contributing to clinical awareness 
of this severe complication after neonatal ASO for TGA. Multicenter and multinational 
collaborations and registries will lead to larger study groups and could provide valuable 
data on disease characteristics, treatment strategies, outcome and its predictors. But, 
such collaborations and registries also come with limitations. Incidence and prevalence 
rates of PAH cannot be determined. Also, treatment and follow-up strategies may differ 
between participating centers and cohorts hampering evaluation of treatment safety/
efficacy and validation of candidate clinical endpoints and treatment goals. Such specific 
issues may be better evaluated in national or single-center cohorts in which standard-
ized follow-up and treatment strategies are used and which allow for a more detailed 
collection of data, although study sizes will be smaller in such cohorts.
For determining efficacy of existing or newly developed PAH-targeted drugs or treat-
ment strategies, RCTs are preferable. Next to the need of validated endpoints, that has 
been addressed previously, obtaining large enough study groups and allowing for rela-
tively short study durations are important challenges. Furthermore, since almost all chil-
dren with PAH receive off-label PAH-targeted therapy and the use of initial combination 
therapy is increasingly considered standard of care it would be ethically problematic to 
withdraw such therapies and trials must allow for the use of background (combination) 
therapy. These challenges may be overcome by so called smart-design trials.58 Such tri-
als do allow for multiple intervention stages, i.e. therapy escalations can be included 




therapy and depending on the treatment response, i.e. whether treatment goals are 
reached or not, patients could either stay on their therapy or escalate quickly to dual or 
triple combination therapy. Consequently, drug efficacy, safety and pharmacokinetics 
and –dynamics could be assessed while securing individual needs.
in conclusion, although outcome of children with PAH has improved since the intro-
duction of the PAH-targeted drugs, outcome in this vulnerable population remains 
unsatisfactory. This thesis increases the available amount of data and improves insights 
in classification, treatment and outcome in pediatric PAH. Furthermore, it presents a new 
candidate clinical endpoint for pediatric RCTs. Therefore, this thesis contributes to the 
development of optimal classification and treatment strategies, which will hopefully 
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